Nastech Pharmaceutical Company, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on its proprietary molecular biology-based drug delivery technology. Its proprietary technologies primarily focus on the intranasal delivery of compounds ranging from small molecules to peptides and proteins. The company and its partners are developing a product portfolio across multiple therapeutic areas, including products targeted for the treatment of osteoporosis, diabetes, obesity, autism, respiratory diseases, and inflammatory conditions. In addition, the company is developing a class of therapeutics utilizing RNA interference technology to down-regulate the expression of diseases causing proteins that are over-expressed in inflammation, viral respiratory infections, and other diseases. Nastech has collaborations with Procter & Gamble Pharmaceuticals, Inc. for the development and commercialization of Parathyroid Hormone (PTH1-34) nasal spray; Amylin Pharmaceuticals, Inc. for development and commercialization of exenatide nasal spray; Novo Nordisk A/S for multiple undisclosed indications; and Par Pharmaceutical Companies, Inc. for distribution of Nastech's generic calcitonin-salmon nasal spray. It also has collaborations with Merck & Co., Inc. and QOL Medical LLC. The company was founded in 1983 and is headquartered in Bothell, Washington.